Does the beginning of the end of atherosclerosis start here?

An early clinical trial demonstrates that gene editing directed at PCSK9—the protein regulating LDL cholesterol—produces dramatic lipid reductions, challenging the conventional model of statin and injectable PCSK9 inhibitor therapy. The therapy targets the root mechanism: it permanently silences PCSK9 expression in hepatic cells, allowing LDL receptors to function at maximum efficiency. For Longevity readers tracking cardiovascular aging biomarkers, this is more than another pharmaceutical option—it represents a therapeutic class shift that could fundamentally alter atherosclerotic risk trajectories across decades. The practical implication is radical: if validated in larger cohorts, this approach could transform atherosclerosis from an inevitable progressive disease into a preventable, potentially reversible condition managed through a single intervention.